Your browser doesn't support javascript.
loading
Lipocalin-2 is increased in amyotrophic lateral sclerosis.
Petrozziello, Tiziana; Mills, Alexandra N; Farhan, Sali M K; Mueller, Kaly A; Granucci, Eric J; Glajch, Kelly E; Chan, James; Chew, Sheena; Berry, James D; Sadri-Vakili, Ghazaleh.
Affiliation
  • Petrozziello T; Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts.
  • Mills AN; Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts.
  • Farhan SMK; Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Mueller KA; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Granucci EJ; Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts.
  • Glajch KE; Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts.
  • Chan J; Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts.
  • Chew S; Biostatistics Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.
  • Berry JD; Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts.
  • Sadri-Vakili G; Sean M. Healey & AMG Center for ALS at Mass General, Massachusetts General Hospital, Boston, Massachusetts.
Muscle Nerve ; 62(2): 272-283, 2020 08.
Article in En | MEDLINE | ID: mdl-32369618
ABSTRACT

BACKGROUND:

The exact mechanisms underlying neuroinflammation and how they contribute to amyotrophic lateral sclerosis (ALS) pathogenesis remain unclear. One possibility is the secretion of neurotoxic factors, such as lipocalin-2 (LCN2), that lead to neuronal death.

METHODS:

LCN2 levels were measured in human postmortem tissue using Western blot, quantitative real time polymerase chain reaction, and immunofluorescence, and in plasma by enzyme-linked immunosorbent assay. SH-SY5Y cells were used to test the pro-inflammatory effects of LCN2.

RESULTS:

LCN2 is increased in ALS postmortem motor cortex, spinal cord, and plasma. Furthermore, we identified several LCN2 variants in ALS patients that may contribute to disease pathogenesis. Lastly, while LCN2 treatment caused cell death and increased pro-inflammatory markers, treatment with an anti-LCN2 antibody prevented these responses in vitro.

CONCLUSIONS:

LCN2 upregulation in ALS postmortem samples and plasma may be an upstream event for triggering neuroinflammation and neuronal death.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Spinal Cord / Lipocalin-2 / Amyotrophic Lateral Sclerosis / Inflammation / Motor Cortex Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Muscle Nerve Year: 2020 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Spinal Cord / Lipocalin-2 / Amyotrophic Lateral Sclerosis / Inflammation / Motor Cortex Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Muscle Nerve Year: 2020 Document type: Article